CHICAGO–(BUSINESS WIRE)–GE HealthCare (Nasdaq: GEHC) today reported financial results for the second quarter ended June 30, 2024.
GE HealthCare President and CEO Peter Arduini said, “In the second quarter, we delivered year-over-year sales growth and margin expansion despite headwinds in the China market. We also reported solid orders growth with particular strength in the U.S., as healthcare systems invest in technologies that enhance patient care and improve productivity. We are pleased with our continued progress in advancing our margin goals, while continuing our investments for future growth.”
Second quarter 2024 total company financial performance
Second quarter 2024 segment financial performance (Unaudited)
|
Segment ($ in millions) |
Imaging |
Ultrasound |
Patient Care Solutions |
Pharmaceutical Diagnostics |
|
Segment Revenues |
$2,596 |
$823 |
$772 |
$639 |
|
YoY % change |
(1)% |
(2)% |
—% |
12% |
|
YoY % Organic* change |
—% |
(1)% |
1% |
14% |
|
Segment EBIT |
$286 |
$178 |
$78 |
$200 |
|
YoY % change |
3% |
(7)% |
(8)% |
31% |
|
Segment EBIT Margin |
11.0% |
21.6% |
10.1% |
31.2% |
|
YoY change |
40 bps |
(120) bps |
(90) bps |
450 bps |
|
YoY refers to year-over-year comparison |
||||
Growth and innovation
Mr. Arduini continued, “The recent Centers for Medicare & Medicaid Services reimbursement proposal has the potential to benefit patients in the U.S. facing cancer, cardiovascular, and neurological diseases. We believe this will unlock the value of our radiopharmaceuticals and PET and SPECT scanners, ultimately enabling more precise diagnostic and treatment planning for patients. We’re optimistic about our pipeline of innovation and ability to bring differentiated solutions to market.”
Recent innovation and commercial highlights
2024 guidance
Today, the Company updates full-year 2024 guidance for Organic revenue growth* and Adjusted EBIT margin* and reaffirms other metrics as follows:
The Company provides its outlook on a non-GAAP basis. Refer to the Non-GAAP Financial Measures in Outlook section below for more details.
Financial rounding
Certain columns and rows in this document may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts.
|
Condensed Consolidated Statements of Income (Unaudited) |
|
|
|||||||||||
|
|
For the three months ended June 30 |
|
For the six months ended June 30 |
||||||||||
|
(In millions, except per share amounts) |
|
2024 |
|
|
2023 |
|
|
|
2024 |
|
|
2023 |
|
|
Sales of products |
$ |
3,207 |
|
$ |
3,213 |
|
|
$ |
6,253 |
|
$ |
6,344 |
|
|
Sales of services |
|
1,632 |
|
|
1,604 |
|
|
|
3,237 |
|
|
3,180 |
|
|
Total revenues |
|
4,839 |
|
|
4,817 |
|
|
|
9,489 |
|
|
9,524 |
|
|
Cost of products |
|
2,045 |
|
|
2,084 |
|
|
|
4,012 |
|
|
4,121 |
|
|
Cost of services |
|
792 |
|
|
793 |
|
|
|
1,574 |
|
|
1,572 |
|
|
Gross profit |
|
2,002 |
|
|
1,940 |
|
|
|
3,904 |
|
|
3,831 |
|
|
Selling, general, and administrative |
|
1,067 |
|
|
1,072 |
|
|
|
2,105 |
|
|
2,134 |
|
|
Research and development |
|
327 |
|
|
298 |
|
|
|
651 |
|
|
568 |
|
|
Total operating expenses |
|
1,395 |
|
|
1,370 |
|
|
|
2,756 |
|
|
2,702 |
|
|
Operating income |
|
608 |
|
|
570 |
|
|
|
1,148 |
|
|
1,129 |
|
|
Interest and other financial charges – net |
|
131 |
|
|
137 |
|
|
|
254 |
|
|
273 |
|
|
Non-operating benefit (income) costs |
|
(101 |
) |
|
(123 |
) |
|
|
(204 |
) |
|
(238 |
) |
|
Other (income) expense – net |
|
(1 |
) |
|
(14 |
) |
|
|
8 |
|
|
(22 |
) |
|
Income before income taxes |
|
578 |
|
|
570 |
|
|
|
1,090 |
|
|
1,116 |
|
|
Benefit (provision) for income taxes |
|
(143 |
) |
|
(137 |
) |
|
|
(267 |
) |
|
(300 |
) |
|
Net income |
|
435 |
|
|
433 |
|
|
|
823 |
|
|
816 |
|
|
Net (income) loss attributable to noncontrolling interests |
|
(7 |
) |
|
(15 |
) |
|
|
(21 |
) |
|
(26 |
) |
|
Net income attributable to GE HealthCare |
|
428 |
|
|
418 |
|
|
|
802 |
|
|
790 |
|
|
Deemed preferred stock dividend of redeemable noncontrolling interest |
|
— |
|
|
— |
|
|
|
— |
|
|
(183 |
) |
|
Net income attributable to GE HealthCare common stockholders |
$ |
428 |
|
$ |
418 |
|
|
$ |
802 |
|
$ |
607 |
|
|
|
|
|
|
|
|
||||||||
|
Earnings per share attributable to GE HealthCare common stockholders: |
|
|
|
|
|
||||||||
|
Basic |
$ |
0.94 |
|
$ |
0.92 |
|
|
$ |
1.76 |
|
$ |
1.34 |
|
|
Diluted |
$ |
0.93 |
|
$ |
0.91 |
|
|
$ |
1.75 |
|
$ |
1.33 |
|
|
Weighted-average number of shares outstanding: |
|
|
|
|
|
||||||||
|
Basic |
|
457 |
|
|
455 |
|
|
|
456 |
|
|
455 |
|
|
Diluted |
|
459 |
|
|
458 |
|
|
|
459 |
|
|
458 |
|
|
Condensed Consolidated Statements of Financial Position (Unaudited) |
|
|||||
|
|
As of |
|||||
|
(In millions, except share and per share amounts) |
June 30, 2024 |
December 31, 2023 |
||||
|
Cash, cash equivalents, and restricted cash |
$ |
2,015 |
|
$ |
2,504 |
|
|
Receivables – net of allowances of $103 and $98 |
|
3,343 |
|
|
3,525 |
|
|
Due from related parties |
|
11 |
|
|
32 |
|
|
Inventories |
|
2,023 |
|
|
1,960 |
|
|
Contract and other deferred assets |
|
977 |
|
|
1,000 |
|
|
All other current assets |
|
437 |
|
|
389 |
|
|
Current assets |
|
8,806 |
|
|
9,410 |
|
|
Property, plant, and equipment – net |
|
2,458 |
|
|
2,500 |
|
|
Goodwill |
|
13,116 |
|
|
12,936 |
|
|
Other intangible assets – net |
|
1,195 |
|
|
1,253 |
|
|
Deferred income taxes |
|
4,365 |
|
|
4,474 |
|
|
All other non-current assets |
|
1,913 |
|
|
1,881 |
|
|
Total assets |
$ |
31,852 |
|
$ |
32,454 |
|
|
Short-term borrowings |
$ |
1,007 |
|
$ |
1,006 |
|
|
Accounts payable |
|
2,824 |
|
|
2,947 |
|
|
Due to related parties |
|
27 |
|
|
99 |
|
|
Contract liabilities |
|
1,876 |
|
|
1,918 |
|
|
Current compensation and benefits |
|
1,235 |
|
|
1,518 |
|
|
All other current liabilities |
|
1,348 |
|
|
1,493 |
|
|
Current liabilities |
|
8,318 |
|
|
8,981 |
|
|
Long-term borrowings |
|
8,233 |
|
|
8,436 |
|
|
Non-current compensation and benefits |
|
5,455 |
|
|
5,782 |
|
|
Deferred income taxes |
|
55 |
|
|
68 |
|
|
All other non-current liabilities |
|
1,796 |
|
|
1,877 |
|
|
Total liabilities |
|
23,858 |
|
|
25,144 |
|
|
Commitments and contingencies |
|
|
||||
|
Redeemable noncontrolling interests |
|
177 |
|
|
165 |
|
|
Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 456,654,068 shares issued and outstanding as of June 30, 2024; 455,342,290 shares issued and outstanding as of December 31, 2023 |
|
5 |
|
|
5 |
|
|
Additional paid-in capital |
|
6,540 |
|
|
6,493 |
|
|
Retained earnings |
|
2,101 |
|
|
1,326 |
|
|
Accumulated other comprehensive income (loss) – net |
|
(845 |
) |
|
(691 |
) |
|
Total equity attributable to GE HealthCare |
|
7,801 |
|
|
7,133 |
|
|
Noncontrolling interests |
|
16 |
|
|
12 |
|
|
Total equity |
|
7,817 |
|
|
7,145 |
|
|
Total liabilities, redeemable noncontrolling interests, and equity |
$ |
31,852 |
|
$ |
32,454 |
|
|
Condensed Consolidated Statements of Cash Flows (Unaudited) |
|
|
||||
|
|
For the six months ended June 30 |
|||||
|
(In millions) |
|
2024 |
|
|
2023 |
|
|
Net income |
$ |
823 |
|
$ |
816 |
|
|
Adjustments to reconcile Net income to Cash from (used for) operating activities |
|
|
||||
|
Depreciation of property, plant, and equipment |
|
137 |
|
|
124 |
|
|
Amortization of intangible assets |
|
160 |
|
|
189 |
|
|
Gain on fair value remeasurement of contingent consideration |
|
(10 |
) |
|
(3 |
) |
|
Net periodic postretirement benefit plan (income) expense |
|
(180 |
) |
|
(207 |
) |
|
Postretirement plan contributions |
|
(170 |
) |
|
(180 |
) |
|
Share-based compensation |
|
70 |
|
|
52 |
|
|
Provision for income taxes |
|
267 |
|
|
300 |
|
|
Cash paid during the year for income taxes |
|
(287 |
) |
|
(271 |
) |
|
Changes in operating assets and liabilities, excluding the effects of acquisitions: |
|
|
||||
|
Receivables |
|
112 |
|
|
(32 |
) |
|
Due from related parties |
|
19 |
|
|
10 |
|
|
Inventories |
|
(116 |
) |
|
(172 |
) |
|
Contract and other deferred assets |
|
12 |
|
|
(64 |
) |
|
Accounts payable |
|
(41 |
) |
|
(40 |
) |
|
Due to related parties |
|
(57 |
) |
|
(11 |
) |
|
Contract liabilities |
|
(20 |
) |
|
111 |
|
|
Current compensation and benefits |
|
(266 |
) |
|
(114 |
) |
|
All other operating activities – net |
|
(155 |
) |
|
(107 |
) |
|
Cash from (used for) operating activities |
|
300 |
|
|
401 |
|
|
Cash flows – investing activities |
|
|
||||
|
Additions to property, plant and equipment and internal-use software |
|
(209 |
) |
|
(213 |
) |
|
Dispositions of property, plant, and equipment |
|
— |
|
|
1 |
|
|
Purchases of businesses, net of cash acquired |
|
(259 |
) |
|
(147 |
) |
|
All other investing activities – net |
|
(69 |
) |
|
9 |
|
|
Cash from (used for) investing activities |
|
(537 |
) |
|
(350 |
) |
|
Cash flows – financing activities |
|
|
||||
|
Net increase (decrease) in borrowings (maturities of 90 days or less) |
|
— |
|
|
(12 |
) |
|
Newly issued debt, net of debt issuance costs (maturities longer than 90 days) |
|
1 |
|
|
2,000 |
|
|
Repayments and other reductions (maturities longer than 90 days) |
|
(156 |
) |
|
(6 |
) |
|
Dividends paid to stockholders |
|
(28 |
) |
|
(14 |
) |
|
Redemption of noncontrolling interests |
|
— |
|
|
(211 |
) |
|
Net transfers (to) from GE |
|
— |
|
|
(1,317 |
) |
|
All other financing activities – net |
|
(27 |
) |
|
6 |
|
|
Cash from (used for) financing activities |
|
(210 |
) |
|
446 |
|
|
Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash |
|
(41 |
) |
|
(3 |
) |
|
Increase (decrease) in cash, cash equivalents, and restricted cash |
|
(488 |
) |
|
494 |
|
|
Cash, cash equivalents, and restricted cash at beginning of year |
|
2,506 |
|
|
1,451 |
|
|
Cash, cash equivalents, and restricted cash as of June 30 |
$ |
2,018 |
|
$ |
1,945 |
|
|
|
|
|
||||
|
Supplemental disclosure of cash flows information |
|
|
||||
|
Cash paid during the year for interest |
$ |
(274 |
) |
$ |
(250 |
) |
|
Non-cash investing activities |
|
|
||||
|
Acquired but unpaid property, plant, and equipment |
$ |
76 |
|
$ |
70 |
|
Non-GAAP Financial Measures
The non-GAAP financial measures presented in this press release are supplemental measures of GE HealthCare’s performance and its liquidity that the Company believes will help investors understand its financial condition, cash flows, and operating results, and assess its future prospects. When read in conjunction with the Company’s U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in GE HealthCare’s underlying businesses and can be used by management as one basis for making financial, operational, and planning decisions. Descriptions of the reported non-GAAP measures are included below.
The Company reports Organic revenue and Organic revenue growth rate to provide management and investors with additional understanding and visibility into the underlying revenue trends of the Company’s established, ongoing operations, as well as provide insights into overall demand for its products and services. To calculate these measures, the Company excludes the effect of acquisitions, dispositions, and foreign currency rate fluctuations.
The Company reports EBIT, Adjusted EBIT, Adjusted EBIT margin, Adjusted net income, Adjusted net income margin, and Adjusted earnings per share to provide management and investors with additional understanding of its business by highlighting the results from ongoing operations and the underlying profitability factors, on a normalized basis. To calculate these measures the Company excludes, and reflects in the detailed reconciliations below, the following adjustments as applicable: Interest and other financial charges – net, Net (income) loss attributable to noncontrolling interests, Non-operating benefit (income) costs, Benefit (provision) for income taxes and certain tax related adjustments, and certain non-recurring and/or non-cash items. GE HealthCare may from time to time consider excluding other non-recurring items to enhance comparability between periods. Adjusted EBIT margin and Adjusted net income margin are calculated by taking Adjusted EBIT, or Adjusted net income, divided by Total revenues for the same period.
The Company reports Adjusted tax expense and Adjusted effective tax rate to provide investors with a better understanding of the normalized tax rate applicable to the business and provide more consistent comparability across periods. Adjusted tax expense excludes the income tax related to the pre-tax income adjustments included as part of Adjusted net income and certain income tax adjustments, such as adjustments to deferred tax assets or liabilities. The Company may from time to time consider excluding other non-recurring tax items to enhance comparability between periods. Adjusted effective tax rate is Adjusted tax expense divided by Income before income taxes less the pre-tax income adjustments referenced above.
The Company reports Free cash flow and Free cash flow conversion to provide management and investors with an important measure of the ability to generate cash on a normalized basis and provide insight into the Company’s flexibility to allocate capital. Free cash flow is Cash from (used for) operating activities including cash flows related to the additions and dispositions of property, plant, and equipment (“PP&E”) and additions of internal-use software. Free cash flow does not represent residual cash flows available for discretionary expenditures, due to the fact that the measure does not deduct the capital required for debt repayments. Free cash flow conversion is calculated by taking Free cash flow divided by Adjusted net income.
Management recognizes that these non-GAAP financial measures have limitations, including that they may be calculated differently by other companies or may be used under different circumstances or for different purposes. In order to compensate for the discussed limitations, management does not consider these measures in isolation from or as alternatives to the comparable financial measures determined in accordance with U.S. GAAP. The detailed reconciliations of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure are provided below, and no single financial measure should be relied on to evaluate our business.
Non-GAAP Financial Reconciliations
|
Organic Revenue* |
|
|
|
|
|
|
|
||||||||
|
Unaudited |
For the three months ended June 30 |
|
For the six months ended June 30 |
||||||||||||
|
($ In millions) |
|
2024 |
|
|
2023 |
% change |
|
|
2024 |
|
|
2023 |
% change |
||
|
Imaging revenues |
$ |
2,596 |
|
$ |
2,620 |
(1 |
)% |
|
$ |
5,062 |
|
$ |
5,116 |
(1 |
)% |
|
Less: Acquisitions(1) |
|
13 |
|
|
— |
|
|
|
13 |
|
|
— |
|
||
|
Less: Dispositions(2) |
|
— |
|
|
— |
|
|
|
— |
|
|
— |
|
||
|
Less: Foreign currency exchange |
|
(37 |
) |
|
— |
|
|
|
(64 |
) |
|
— |
|
||
|
Imaging Organic revenue* |
$ |
2,620 |
|
$ |
2,620 |
— |
% |
|
$ |
5,113 |
|
$ |
5,116 |
— |
% |
|
Ultrasound revenues |
$ |
823 |
|
$ |
839 |
(2 |
)% |
|
$ |
1,647 |
|
$ |
1,698 |
(3 |
)% |
|
Less: Acquisitions(1) |
|
— |
|
|
— |
|
|
|
— |
|
|
— |
|
||
|
Less: Dispositions(2) |
|
— |
|
|
— |
|
|
|
— |
|
|
— |
|
||
|
Less: Foreign currency exchange |
|
(8 |
) |
|
— |
|
|
|
(13 |
) |
|
— |
|
||
|
Ultrasound Organic revenue* |
$ |
831 |
|
$ |
839 |
(1 |
)% |
|
$ |
1,659 |
|
$ |
1,698 |
(2 |
)% |
|
PCS revenues |
$ |
772 |
|
$ |
770 |
— |
% |
|
$ |
1,519 |
|
$ |
1,551 |
(2 |
)% |
|
Less: Acquisitions(1) |
|
— |
|
|
— |
|
|
|
— |
|
|
— |
|
||
|
Less: Dispositions(2) |
|
— |
|
|
— |
|
|
|
— |
|
|
— |
|
||
|
Less: Foreign currency exchange |
|
(2 |
) |
|
— |
|
|
|
(4 |
) |
|
— |
|
||
|
PCS Organic revenue* |
$ |
775 |
|
$ |
770 |
1 |
% |
|
$ |
1,523 |
|
$ |
1,551 |
(2 |
)% |
|
PDx revenues |
$ |
639 |
|
$ |
568 |
12 |
% |
|
$ |
1,238 |
|
$ |
1,126 |
10 |
% |
|
Less: Acquisitions(1) |
|
— |
|
|
— |
|
|
|
— |
|
|
— |
|
||
|
Less: Dispositions(2) |
|
— |
|
|
— |
|
|
|
— |
|
|
— |
|
||
|
Less: Foreign currency exchange |
|
(7 |
) |
|
— |
|
|
|
(8 |
) |
|
— |
|
||
|
PDx Organic revenue* |
$ |
646 |
|
$ |
568 |
14 |
% |
|
$ |
1,246 |
|
$ |
1,126 |
11 |
% |
|
Other revenues |
$ |
9 |
|
$ |
20 |
(53 |
)% |
|
$ |
24 |
|
$ |
33 |
(27 |
)% |
|
Less: Acquisitions(1) |
|
— |
|
|
— |
|
|
|
— |
|
|
— |
|
||
|
Less: Dispositions(2) |
|
— |
|
|
— |
|
|
|
— |
|
|
— |
|
||
|
Less: Foreign currency exchange |
|
— |
|
|
— |
|
|
|
— |
|
|
— |
|
||
|
Other Organic revenue* |
$ |
9 |
|
$ |
20 |
(53 |
)% |
|
$ |
24 |
|
$ |
33 |
(27 |
)% |
|
Total revenues |
$ |
4,839 |
|
$ |
4,817 |
— |
% |
|
$ |
9,489 |
|
$ |
9,524 |
— |
% |
|
Less: Acquisitions(1) |
|
13 |
|
|
— |
|
|
|
14 |
|
|
— |
|
||
|
Less: Dispositions(2) |
|
— |
|
|
— |
|
|
|
— |
|
|
— |
|
||
|
Less: Foreign currency exchange |
|
(54 |
) |
|
— |
|
|
|
(89 |
) |
|
— |
|
||
|
Organic revenue* |
$ |
4,881 |
|
$ |
4,817 |
1 |
% |
|
$ |
9,565 |
|
$ |
9,524 |
— |
% |
|
(1) |
Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction. |
|
(2) |
Represents revenues attributable to dispositions for the four quarters preceding the disposition date. |
|
Adjusted EBIT* |
|
|
|||||||||||||||
|
Unaudited |
For the three months ended June 30 |
|
For the six months ended June 30 |
||||||||||||||
|
($ In millions) |
|
2024 |
|
|
2023 |
|
% change |
|
|
2024 |
|
|
2023 |
|
% change |
||
|
Net income attributable to GE HealthCare |
$ |
428 |
|
$ |
418 |
|
2 |
% |
|
$ |
802 |
|
$ |
790 |
|
2 |
% |
|
Add: Interest and other financial charges – net |
|
131 |
|
|
137 |
|
|
|
|
254 |
|
|
273 |
|
|
||
|
Add: Non-operating benefit (income) costs |
|
(101 |
) |
|
(123 |
) |
|
|
|
(204 |
) |
|
(238 |
) |
|
||
|
Less: Benefit (provision) for income taxes |
|
(143 |
) |
|
(137 |
) |
|
|
|
(267 |
) |
|
(300 |
) |
|
||
|
Less: Net (income) loss attributable to noncontrolling interests |
|
(7 |
) |
|
(15 |
) |
|
|
|
(21 |
) |
|
(26 |
) |
|
||
|
EBIT* |
$ |
608 |
|
$ |
584 |
|
4 |
% |
|
$ |
1,140 |
|
$ |
1,151 |
|
(1 |
)% |
|
Add: Restructuring costs(1) |
|
29 |
|
|
19 |
|
|
|
|
68 |
|
|
31 |
|
|
||
|
Add: Acquisition and disposition-related charges (benefits)(2) |
|
(3 |
) |
|
(2 |
) |
|
|
|
(3 |
) |
|
(1 |
) |
|
||
|
Add: Spin-Off and separation costs(3) |
|
67 |
|
|
72 |
|
|
|
|
126 |
|
|
130 |
|
|
||
|
Add: (Gain) loss on business and asset dispositions(4) |
|
— |
|
|
— |
|
|
|
|
— |
|
|
— |
|
|
||
|
Add: Amortization of acquisition-related intangible assets |
|
35 |
|
|
32 |
|
|
|
|
66 |
|
|
63 |
|
|
||
|
Add: Investment revaluation (gain) loss(5) |
|
6 |
|
|
6 |
|
|
|
|
26 |
|
|
1 |
|
|
||
|
Adjusted EBIT* |
$ |
742 |
|
$ |
711 |
|
4 |
% |
|
$ |
1,423 |
|
$ |
1,375 |
|
3 |
% |
|
Net income margin |
|
8.9 |
% |
|
8.7 |
% |
20 bps |
|
|
8.5 |
% |
|
8.3 |
% |
20 bps |
||
|
Adjusted EBIT margin* |
|
15.3 |
% |
|
14.8 |
% |
60 bps |
|
|
15.0 |
% |
|
14.4 |
% |
60 bps |
||
|
(1) |
Consists of severance, facility closures, and other charges associated with restructuring programs. |
|
(2) |
Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions. |
|
(3) |
Costs incurred in the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs. |
|
(4) |
Consists of gains and losses resulting from the sale of assets and investments. |
|
(5) |
Primarily relates to valuation adjustments for equity investments. |
|
Adjusted Net Income* |
|
|
|||||||||||||||
|
Unaudited |
For the three months ended June 30 |
|
For the six months ended June 30 |
||||||||||||||
|
($ In millions) |
|
2024 |
|
|
2023 |
|
% change |
|
|
2024 |
|
|
2023 |
|
% change |
||
|
Net income attributable to GE HealthCare |
$ |
428 |
|
$ |
418 |
|
2 |
% |
|
$ |
802 |
|
$ |
790 |
|
2 |
% |
|
Add: Non-operating benefit (income) costs |
|
(101 |
) |
|
(123 |
) |
|
|
|
(204 |
) |
|
(238 |
) |
|
||
|
Add: Restructuring costs(1) |
|
29 |
|
|
19 |
|
|
|
|
68 |
|
|
31 |
|
|
||
|
Add: Acquisition and disposition-related charges (benefits)(2) |
|
(3 |
) |
|
(2 |
) |
|
|
|
(3 |
) |
|
(1 |
) |
|
||
|
Add: Spin-Off and separation costs(3) |
|
67 |
|
|
72 |
|
|
|
|
126 |
|
|
130 |
|
|
||
|
Add: (Gain) loss on business and asset dispositions(4) |
|
— |
|
|
— |
|
|
|
|
— |
|
|
— |
|
|
||
|
Add: Amortization of acquisition-related intangible assets |
|
35 |
|
|
32 |
|
|
|
|
66 |
|
|
63 |
|
|
||
|
Add: Investment revaluation (gain) loss(5) |
|
6 |
|
|
6 |
|
|
|
|
26 |
|
|
1 |
|
|
||
|
Add: Tax effect of reconciling items |
|
(1 |
) |
|
(3 |
) |
|
|
|
(10 |
) |
|
1 |
|
|
||
|
Add: Certain tax adjustments(6) |
|
— |
|
|
— |
|
|
|
|
— |
|
|
30 |
|
|
||
|
Adjusted net income* |
$ |
459 |
|
$ |
419 |
|
10 |
% |
|
$ |
872 |
|
$ |
807 |
|
8 |
% |
|
Adjusted net income margin* |
|
9.5 |
% |
|
8.7 |
% |
80 bps |
|
|
9.2 |
% |
|
8.5 |
% |
70 bps |
||
|
(1) |
Consists of severance, facility closures, and other charges associated with restructuring programs. |
|
(2) |
Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions. |
|
(3) |
Costs incurred in the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs. |
|
(4) |
Consists of gains and losses resulting from the sale of assets and investments. |
|
(5) |
Primarily relates to valuation adjustments for equity investments. |
|
(6) |
Consists of certain income tax adjustments, including the accrual of a deferred tax liability on the prior period earnings of certain of the Company’s foreign subsidiaries for which the Company is no longer permanently reinvested and the impact of adjusting deferred tax assets and liabilities to stand-alone GE HealthCare tax rates. |
|
Adjusted Earnings Per Share* |
|
|
|
|
|
|
|||||||||||
|
Unaudited |
For the three months ended June 30 |
|
For the six months ended June 30 |
||||||||||||||
|
(In dollars, except shares outstanding presented in millions) |
|
2024 |
|
|
2023 |
|
$ change |
|
|
2024 |
|
|
2023 |
|
$ change |
||
|
Diluted earnings per share |
$ |
0.93 |
|
$ |
0.91 |
|
$ |
0.02 |
|
$ |
1.75 |
|
$ |
1.33 |
|
$ |
0.42 |
|
Add: Deemed preferred stock dividend of redeemable noncontrolling interest |
|
— |
|
|
— |
|
|
|
|
— |
|
|
0.40 |
|
|
||
|
Add: Non-operating benefit (income) costs |
|
(0.22 |
) |
|
(0.27 |
) |
|
|
|
(0.44 |
) |
|
(0.52 |
) |
|
||
|
Add: Restructuring costs(1) |
|
0.06 |
|
|
0.04 |
|
|
|
|
0.15 |
|
|
0.07 |
|
|
||
|
Add: Acquisition and disposition-related charges (benefits)(2) |
|
(0.01 |
) |
|
(0.00 |
) |
|
|
|
(0.01 |
) |
|
(0.00 |
) |
|
||
|
Add: Spin-Off and separation costs(3) |
|
0.15 |
|
|
0.16 |
|
|
|
|
0.28 |
|
|
0.28 |
|
|
||
|
Add: (Gain) loss on business and asset dispositions(4) |
|
— |
|
|
— |
|
|
|
|
— |
|
|
— |
|
|
||
|
Add: Amortization of acquisition-related intangible assets |
|
0.08 |
|
|
0.07 |
|
|
|
|
0.14 |
|
|
0.14 |
|
|
||
|
Add: Investment revaluation (gain) loss(5) |
|
0.01 |
|
|
0.01 |
|
|
|
|
0.06 |
|
|
0.00 |
|
|
||
|
Add: Tax effect of reconciling items |
|
(0.00 |
) |
|
(0.01 |
) |
|
|
|
(0.02 |
) |
|
0.00 |
|
|
||
|
Add: Certain tax adjustments(6) |
|
— |
|
|
— |
|
|
|
|
— |
|
|
0.07 |
|
|
||
|
Adjusted earnings per share* |
$ |
1.00 |
|
$ |
0.92 |
|
$ |
0.09 |
|
$ |
1.90 |
|
$ |
1.76 |
|
$ |
0.14 |
|
Diluted weighted-average shares outstanding |
|
459 |
|
|
458 |
|
|
|
|
459 |
|
|
458 |
|
|
||
|
(1) |
Consists of severance, facility closures, and other charges associated with restructuring programs. |
|
(2) |
Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions. |
|
(3) |
Costs incurred in the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs. |
|
(4) |
Consists of gains and losses resulting from the sale of assets and investments. |
|
(5) |
Primarily relates to valuation adjustments for equity investments. |
|
(6) |
Consists of certain income tax adjustments, including the accrual of a deferred tax liability on the prior period earnings of certain of the Company’s foreign subsidiaries for which the Company is no longer permanently reinvested and the impact of adjusting deferred tax assets and liabilities to stand-alone GE HealthCare tax rates. |
Contacts
Investor Relations Contact:
Carolynne Borders
+1-631-662-4317
carolynne.borders@gehealthcare.com
Media Contact:
Jennifer Fox
+1-414-530-3027
jennifer.r.fox@gehealthcare.com
CAMPBELL, Calif.--(BUSINESS WIRE)--Vision Products, LLC, a leader in head/helmet mounted displays (HMDs) for military training…
LOS ANGELES--(BUSINESS WIRE)--The GRAMMY Museum® announced today the expansion of its acclaimed GRAMMY Camp® ,…
Metinteractive, which provides strategic solutions for architecture, communication and technology, drew from its extensive experience…
SINGAPORE and ABU DHABI, UAE, Nov. 21, 2024 /PRNewswire/ -- Mega Matrix Inc. (NYSE American: MPU) today…
VANCOUVER, BC, Nov. 21, 2024 /PRNewswire/ -- Wondershare Filmora, a leading video editing software, and…
SAN JOSE, Calif., Nov. 21, 2024 /PRNewswire/ -- LetinAR, a leader in optical technology for…